Sihuan Pharma Files IND for New Anti-Hypertensive Drug

Sihuan Pharmaceutical announced its application to begin clinical trials of a new treatment for hypertension was accepted by the SFDA. The company developed Tylerdipine Hydrochloride, a calcium channel blocker, in its own facilities. Sihuan hopes to obtain approval to begin the China trials by the end of 2013, and the company will also seek to run tests of the product in the US. More details.... Stock Symbol: (HK: 0460) Share this with colleagues: var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});